{"transactions":[{"id":804269,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:14:12.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1744627/000119312526164275/ownership.xml","form_type":"4"}},{"id":804268,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:14:12.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164275","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1744627/000119312526164275/ownership.xml","form_type":"4"}},{"id":1440888,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-08-05T16:20:26.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":81065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, (a) 50% of each outstanding award of restricted stock units (\"RSUs\") that was granted on or after December 6, 2023 was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of shares underlying such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement, and (b) the remaining 50% was assumed by Parent and converted into RSUs with respect to shares of the Parent's common stock in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":81065},"source":{"system":"sec-edgar","filing":"0000950170-24-090787","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090787/ownership.xml","form_type":"4"}},{"id":1440887,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-05T16:20:26.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":95931,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of common stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":95931},"source":{"system":"sec-edgar","filing":"0000950170-24-090787","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090787/ownership.xml","form_type":"4"}},{"id":1440886,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-08-05T16:20:26.000Z","date":"2024-08-01","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":45727,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated December 6, 2023, by and among AbbVie Inc. (\"Parent\"), Symphony Harlan LLC, Symphony Harlan Merger Sub Inc. (\"Merger Sub\") and Cerevel Therapeutics Holdings, Inc. (\"Issuer\"), on August 1, 2024 (the \"Effective Time\"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock was cancelled and converted into the right to receive $45.00 in cash (the \"Merger Consideration\"), without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-090787","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024090787/ownership.xml","form_type":"4"}},{"id":1673141,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2024-01-23T17:37:44.000Z","date":"2024-01-19","kind":"grant","planned":false,"acquired":true,"shares":81065,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of January 19, 2025, January 19, 2026, January 19, 2027 and January 19, 2028, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":81065,"derivative":{"underlying":"Common Stock","underlying_shares":81065},"source":{"system":"sec-edgar","filing":"0000950170-24-006677","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017024006677/ownership.xml","form_type":"4"}},{"id":1702299,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-12-21T20:26:18.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":false,"shares":23847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":23847},"source":{"system":"sec-edgar","filing":"0000950170-23-072380","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072380/ownership.xml","form_type":"4"}},{"id":1702298,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-21T20:26:18.000Z","date":"2023-12-19","kind":"exercise","planned":false,"acquired":true,"shares":23847,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"In order to mitigate the impact of Sections 280G and 4999 of the Internal Revenue Code of 1986, as amended, in connection with the transactions contemplated by the Agreement and Plan of Merger, dated as of December 6, 2023, by and among Cerevel Therapeutics Holdings, Inc. (the \"Issuer\"), AbbVie Inc., Symphony Harlan LLC and Symphony Harlan Merger Sub Inc., the restricted stock units (\"RSUs\") held by the Reporting Person vested in full on December 19, 2023, subject to certain repayment conditions in the event that the Reporting Person's employment terminates for any reason prior to the date the RSUs otherwise would vest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Each RSU represented the contingent right to receive one share of the Issuer's common stock."}],"balance_after":45727,"source":{"system":"sec-edgar","filing":"0000950170-23-072380","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023072380/ownership.xml","form_type":"4"}},{"id":1813900,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-08-07T17:11:49.000Z","date":"2023-08-04","kind":"purchase","planned":false,"acquired":true,"shares":21880,"price":22.9339,"value":501793.732,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.85 - $22.96. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":21880,"source":{"system":"sec-edgar","filing":"0000950170-23-039165","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023039165/ownership.xml","form_type":"4"}},{"id":1834018,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Restricted Stock Units","published_at":"2023-07-06T16:16:25.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":23847,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares reported in this transaction represent Restricted Stock Units (\"RSUs\") granted under the Cerevel Therapeutics Holdings, Inc. 2020 Equity Incentive Plan (the \"Plan\"). Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs vest in four equal annual installments on each of July 3, 2024, July 3, 2025, July 3, 2026 and July 3, 2027, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":23847,"derivative":{"underlying":"Common Stock","underlying_shares":23847},"source":{"system":"sec-edgar","filing":"0000950170-23-032016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023032016/ownership.xml","form_type":"4"}},{"id":1834017,"issuer":{"id":15182,"kind":"organization","name":"Cerevel Therapeutics Holdings, Inc.","symbol":"CERE"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-07-06T16:16:25.000Z","date":"2023-07-03","kind":"grant","planned":false,"acquired":true,"shares":95931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on July 3, 2024, with the remainder vesting in thirty-six (36) monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":95931,"derivative":{"exercise_price":31.45,"expiration_date":"2033-07-03","underlying":"Common Stock","underlying_shares":95931},"source":{"system":"sec-edgar","filing":"0000950170-23-032016","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1805387/000095017023032016/ownership.xml","form_type":"4"}},{"id":2570841,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:29:46.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This option was granted on March 9, 2021. This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025."}],"balance_after":0,"derivative":{"exercise_price":23.82,"expiration_date":"2031-03-08","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-056057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/doc4.xml","form_type":"4"}},{"id":2570840,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:29:46.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"This option was granted on March 3, 2020. This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023."}],"balance_after":0,"derivative":{"exercise_price":7.66,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-21-056057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/doc4.xml","form_type":"4"}},{"id":2570839,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:29:46.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option was granted on March 8, 2019. This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023."}],"balance_after":0,"derivative":{"exercise_price":7.95,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-21-056057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/doc4.xml","form_type":"4"}},{"id":2570838,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:29:46.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":69953,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on March 7, 2018. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 7, 2019 and the remainder vesting in equal monthly installments through March 7, 2022."}],"balance_after":0,"derivative":{"exercise_price":8.34,"expiration_date":"2028-03-06","underlying":"Common Stock","underlying_shares":69953},"source":{"system":"sec-edgar","filing":"0001209191-21-056057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/doc4.xml","form_type":"4"}},{"id":2570837,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-09-14T19:29:46.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":219652,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on December 22, 2017. The shares underlying the option became fully vested on March 9, 2021."}],"balance_after":0,"derivative":{"exercise_price":7.39,"expiration_date":"2027-12-21","underlying":"Common Stock","underlying_shares":219652},"source":{"system":"sec-edgar","filing":"0001209191-21-056057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/doc4.xml","form_type":"4"}},{"id":2570836,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Common Stock","published_at":"2021-09-14T19:29:46.000Z","date":"2021-09-14","kind":"sale","acquired":false,"shares":71833,"price":38,"value":2729654.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."},{"field":"shares","element":"transactionShares","label":"F1","text":"As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the \"Tender Offer\"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-21-056057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121056057/doc4.xml","form_type":"4"}},{"id":2800073,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-09T20:23:06.000Z","date":"2021-03-09","kind":"grant","acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on March 9, 2022, and in thirty-six equal monthly installments thereafter as to the remaining shares though March 9, 2025."}],"balance_after":90000,"derivative":{"exercise_price":23.82,"expiration_date":"2031-03-09","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001209191-21-019299","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919121019299/doc4.xml","form_type":"4"}},{"id":3224743,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Operating Officer, CLO","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2020-03-05T19:49:36.000Z","date":"2020-03-03","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on December 11, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through December 11, 2023."}],"balance_after":150000,"derivative":{"exercise_price":7.66,"expiration_date":"2030-03-02","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-20-016799","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919120016799/doc4.xml","form_type":"4"}},{"id":3599421,"issuer":{"id":135439,"kind":"organization","name":"Translate Bio, Inc.","symbol":"TBIO"},"owners":[{"id":51903,"kind":"person","name":"Burgess Paul D.","position":1,"cik":"0001744627","reported_name":"Burgess Paul D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":true,"officer_title":"Chief Legal Officer","other_text":"Secretary"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-12T18:10:33.000Z","date":"2019-03-08","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option will vest as to 25% of the shares on March 8, 2020, and in thirty-six equal monthly installments thereafter as to the remaining shares through March 8, 2023."}],"balance_after":150000,"derivative":{"exercise_price":7.95,"expiration_date":"2029-03-07","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-19-018950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1693415/000120919119018950/doc4.xml","form_type":"4"}}]}